Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom

作者：Wolfgang P. Fendler, Clemens Kratochwil, Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P. Baum, Matthias Schmidt, Andreas Pfestroff, Ulf Lützen, Vikas Prasad, Alexander Heinzel, Martin Heuschkel, Juri Ruf, Peter Bartenstein, Bernd J. Krause · 发表于：Nuklearmedizin - NuclearMedicine · 年份：2016 · DOI：10.1055/s-0037-1616480 · 被引用次数：116 · 研究领域：Prostate Cancer Treatment and Research、Radiopharmaceutical Chemistry and Applications、Lung Cancer Treatments and Mutations

Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in patients with metastatic castration-resistant prostate cancer (mCRPC) after exhaustion of other options. German University Clinics offer RLT since 2013 on a compassionate use basis. The present consensus document includes recommendations for RLT with 177Lu-PSMA-617. These consensus statements were developed by an expert panel formed by the German Society of Nuclear Medicine (DGN) in December 2015. Statements include recommendations for indication, baseline tests, therapy protocol, concomitant therapy, dosimetry, and follow-up. Consensus recommendations aim to inform the attending medical staff, standardize 177Lu-PSMA-617 RLT, and improve quality of individual patient care.